Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clopidogrel for Preventing Exacerbations in Severe COPD
NCT06021990Phase 3Unknown
- Start
- Oct 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in chronic obstructive pulmonary disease (COPD) comparing Clopidogrel group with Standard of Care (2 arms). Primary endpoint: Number of acute exacerbations of COPD at 28 days. Status: unknown.
02
Drugs
clopidogrel
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06021990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06021990.